{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:28:42Z","timestamp":1778819322068,"version":"3.51.4"},"reference-count":53,"publisher":"Media Sphere Publishing House","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["S.S. Korsakov J. Neuro. Psych."],"published-print":{"date-parts":[[2025,5,27]]},"abstract":"<jats:p>Currently, the treatment of Alzheimer\u2019s disease (AD) is limited to symptomatic therapy with acetylcholinesterase inhibitors and memantine, which contribute to a temporary improvement in cognitive functions and increased independence in everyday life but have little effect on the progression rate of the neurodegenerative process. The purpose of the review is to analyze current studies of pathogenetic (disease-modifying therapy) of AD. According to modern concepts, AD pathogenesis is associated with the accumulation of amyloid protein, hyperphosphorylation of tau protein, neuroinflammation, mitochondrial dysfunction, etc. The most promising pathogenetic therapy is currently considered anti-amyloid antibodies, anti-tau therapies, and antidiabetic and anti-inflammatory therapy. Anti-amyloid therapies such as aducanumab, lecanumab, and donanemab have recently been officially approved for practical use in some countries around the world. Therapeutic strategies for tau protein-related disorders, neuroinflammation, insulin resistance, and other neurodegeneration mechanisms are also being actively studied. Along with drug therapy, noninvasive brain stimulation methods such as transcranial magnetic stimulation and transcranial electrical stimulation, which have a high safety profile and proven effectiveness, are actively developing.<\/jats:p>","DOI":"10.17116\/jnevro202512504254","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T05:14:52Z","timestamp":1748322892000},"page":"54","source":"Crossref","is-referenced-by-count":1,"special_numbering":"Vyp. 2","title":["Prospects for treating Alzheimer\u2019s disease"],"prefix":"10.17116","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0834-4030","authenticated-orcid":false,"given":"N.V.","family":"Vakhnina","sequence":"first","affiliation":[{"name":"Sechenov First Moscow State Medical University (Sechenov University)","place":["Moscow, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5897-7594","authenticated-orcid":false,"given":"D.K.","family":"Novikov","sequence":"additional","affiliation":[{"name":"Sechenov First Moscow State Medical University (Sechenov University)","place":["Moscow, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0900-4721","authenticated-orcid":false,"given":"K.A.","family":"Vekhova","sequence":"additional","affiliation":[{"name":"Sechenov First Moscow State Medical University (Sechenov University)","place":["Moscow, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6185-5247","authenticated-orcid":false,"given":"A.M.","family":"Zhuk","sequence":"additional","affiliation":[{"name":"Sechenov First Moscow State Medical University (Sechenov University)","place":["Moscow, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4349-9038","authenticated-orcid":false,"given":"D.L.","family":"Klimanovich","sequence":"additional","affiliation":[{"name":"Sechenov First Moscow State Medical University (Sechenov University)","place":["Moscow, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4950-144X","authenticated-orcid":false,"given":"A.I.","family":"Isaikin","sequence":"additional","affiliation":[{"name":"Sechenov First Moscow State Medical University (Sechenov University)","place":["Moscow, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8447-3264","authenticated-orcid":false,"given":"V.V.","family":"Zakharov","sequence":"additional","affiliation":[{"name":"Sechenov First Moscow State Medical University (Sechenov University)","place":["Moscow, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6743","reference":[{"key":"key-10.17116\/jnevro202512504254-1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2012.11.007"},{"key":"key-10.17116\/jnevro202512504254-2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-180802"},{"key":"key-10.17116\/jnevro202512504254-3","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00015.2020"},{"key":"key-10.17116\/jnevro202512504254-4","doi-asserted-by":"publisher","DOI":"10.1096\/fj.05-3735fje"},{"key":"key-10.17116\/jnevro202512504254-5","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.21-04-01179.2001"},{"key":"key-10.17116\/jnevro202512504254-6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.4.1470"},{"key":"key-10.17116\/jnevro202512504254-7","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00024.2003"},{"key":"key-10.17116\/jnevro202512504254-8","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25245789"},{"key":"key-10.17116\/jnevro202512504254-9","doi-asserted-by":"publisher","DOI":"10.1126\/science.1062097"},{"key":"key-10.17116\/jnevro202512504254-10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.06.036"},{"key":"key-10.17116\/jnevro202512504254-11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2013.5847"},{"key":"key-10.17116\/jnevro202512504254-12","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101619"},{"key":"key-10.17116\/jnevro202512504254-13","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2020.94659"},{"key":"key-10.17116\/jnevro202512504254-14","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-018-1188-4"},{"key":"key-10.17116\/jnevro202512504254-15","unstructured":"Search for: Alzheimer Disease, Study completion from 10\/12\/2024 to 10\/13\/2080. List Results. ClinicalTrials.gov. Accessed October 13,2024.  Available et:  https:\/\/clinicaltrials.gov\/search?cond=Alzheimer%20Disease&studyComp=2024-10-12_2080-10-13"},{"key":"key-10.17116\/jnevro202512504254-16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22158208"},{"key":"key-10.17116\/jnevro202512504254-17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2024.01.047"},{"key":"key-10.17116\/jnevro202512504254-18","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201606210"},{"key":"key-10.17116\/jnevro202512504254-19","doi-asserted-by":"publisher","DOI":"10.1126\/science.1566067"},{"key":"key-10.17116\/jnevro202512504254-20","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05999-z"},{"key":"key-10.17116\/jnevro202512504254-21","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-018-1292-6"},{"key":"key-10.17116\/jnevro202512504254-22","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1090-04.2004"},{"key":"key-10.17116\/jnevro202512504254-23","doi-asserted-by":"publisher","DOI":"10.1023\/a:1023203122036"},{"key":"key-10.17116\/jnevro202512504254-24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304839"},{"key":"key-10.17116\/jnevro202512504254-25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705971"},{"key":"key-10.17116\/jnevro202512504254-26","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201406357"},{"key":"key-10.17116\/jnevro202512504254-27","unstructured":"Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer\u2019s Disease. Accessed November 29, 2024.  https:\/\/www.prnewswire.com\/news-releases\/lilly-provides-update-on-a4-study-of-solanezumab-for-preclinical-alzheimers-disease-301766069.html"},{"key":"key-10.17116\/jnevro202512504254-28","unstructured":"Ad hoc announcement pursuant to Art. 53 LR Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer\u2019s disease. Accessed November 29, 2024.  https:\/\/www.roche.com\/media\/releases\/med-cor-2022-11-14"},{"key":"key-10.17116\/jnevro202512504254-29","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12843"},{"key":"key-10.17116\/jnevro202512504254-30","doi-asserted-by":"publisher","DOI":"10.1538\/expanim.22-0164"},{"key":"key-10.17116\/jnevro202512504254-31","unstructured":"FDA approves treatment for adults with Alzheimer\u2019s disease. FDA. Accessed October 23,2024.  https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-adults-alzheimers-disease"},{"key":"key-10.17116\/jnevro202512504254-32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-24501-0"},{"key":"key-10.17116\/jnevro202512504254-33","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.30"},{"key":"key-10.17116\/jnevro202512504254-34","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9343514"},{"key":"key-10.17116\/jnevro202512504254-35","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-140741"},{"key":"key-10.17116\/jnevro202512504254-36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"key-10.17116\/jnevro202512504254-37","unstructured":"Trontinemab. ALZFORUM. Accessed November 29, 2024.  https:\/\/www.alzforum.org\/therapeutics\/trontinemab"},{"key":"key-10.17116\/jnevro202512504254-38","unstructured":"Study Details. A Study of Donanemab (LY3002813) in Participants With Early Alzheimer\u2019s Disease (TRAILBLAZER-ALZ 2). ClinicalTrials.gov. Accessed December 13, 2024.  https:\/\/clinicaltrials.gov\/study\/NCT04437511?cond=NCT04437511&rank=1"},{"key":"key-10.17116\/jnevro202512504254-39","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.93"},{"key":"key-10.17116\/jnevro202512504254-40","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-023-01405-0"},{"key":"key-10.17116\/jnevro202512504254-41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100708"},{"key":"key-10.17116\/jnevro202512504254-42","doi-asserted-by":"publisher","DOI":"10.1002\/ALZ.057492"},{"key":"key-10.17116\/jnevro202512504254-43","doi-asserted-by":"publisher","DOI":"10.1192\/BJO.2023.227"},{"key":"key-10.17116\/jnevro202512504254-44","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.102113"},{"key":"key-10.17116\/jnevro202512504254-45","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2018.00083"},{"key":"key-10.17116\/jnevro202512504254-46","unstructured":"Lehrer S, Rheinstein PH. Nasal Steroids as a Possible Treatment for Alzheimer\u2019s Disease. Discov Med. 2017;24(132):147-152"},{"key":"key-10.17116\/jnevro202512504254-47","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2020.101067"},{"key":"key-10.17116\/jnevro202512504254-48","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.9220"},{"key":"key-10.17116\/jnevro202512504254-49","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00922-4"},{"key":"key-10.17116\/jnevro202512504254-50","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.598135"},{"key":"key-10.17116\/jnevro202512504254-51","doi-asserted-by":"publisher","DOI":"10.1109\/TNSRE.2023.3265378"},{"key":"key-10.17116\/jnevro202512504254-52","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26411"},{"key":"key-10.17116\/jnevro202512504254-53","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-021-01198-3"}],"container-title":["S.S. Korsakov Journal of Neurology and Psychiatry"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T05:15:16Z","timestamp":1748322916000},"score":1,"resource":{"primary":{"URL":"https:\/\/mediasphera.ru\/issues\/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova-2\/2025\/4-2\/1199772982025042054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,5,27]]}},"alternative-id":["10.17116\/jnevro202512504254"],"URL":"https:\/\/doi.org\/10.17116\/jnevro202512504254","relation":{},"ISSN":["1997-7298"],"issn-type":[{"value":"1997-7298","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,27]]}}}